Regeneron Pharma (REGN) - 500 Beiträge pro Seite
eröffnet am 03.04.03 17:11:55 von
neuester Beitrag 03.01.04 19:46:57 von
neuester Beitrag 03.01.04 19:46:57 von
Beiträge: 13
ID: 716.649
ID: 716.649
Aufrufe heute: 0
Gesamt: 992
Gesamt: 992
Aktive User: 0
ISIN: US75886F1075 · WKN: 881535 · Symbol: RGO
836,20
EUR
-0,40 %
-3,40 EUR
Letzter Kurs 11:29:58 Tradegate
Neuigkeiten
| Regeneron Pharmaceuticals Aktien jetzt im kostenlosen Demokonto handeln!Anzeige |
17.04.24 · Business Wire (engl.)  |
07.04.24 · globenewswire |
01.04.24 · globenewswire |
25.03.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3.000,00 | +74.900,00 | |
| 0,9300 | +54,46 | |
| 2,4700 | +33,51 | |
| 3,5000 | +30,60 | |
| 0,7000 | +23,28 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,8501 | -17,47 | |
| 3,4400 | -17,70 | |
| 5,0550 | -22,71 | |
| 6,0500 | -22,93 | |
| 1,2250 | -38,44 |
Feedback
Die Aktie ist innerhalb von 3 Tagen von 20 USD auf <7 USD zurückgefallen, da ein Phase III - Trial schlecht ausgefallen ist. Mittlerweile ist sie quasi auf Cash Niveau (295 Mio, 6.70 USD pro Aktie) angelangt. In der Pipeline hat es noch weitere Kandidaten und Novartis hat sich vor kurzem an der Gesellschaft beteiligt. Für mich ein Kandidat, der auch mal zügig wieder 50% zulegen kann. Mein erstes Kursziel sehe ich nach überschreiten von 9 USD bei 11/12 USD.
Greetinxx Heinerle2
Greetinxx Heinerle2
Das Dingen verliert fast 100 Mio im Jahr. Wenn dieses Trial Teil so wichtig war. Dann heisst es bald goodbye baby!
nö nö
kein Griff ins fallende Messer!
see you again bei 5 $
Mal eine kleine Wasserstandsmeldung: Die Aktie ist heute (nachdem sie zuvor zwischen 6.50-7.00 USD eine Bodenbildung erarbeitet hat) unter massiven Umsätzen nach oben abgegangen und hat quasi auf Tageshoch nahe 10 USD geschlossen. Ich gehe davon aus, daß morgen noch ein paar Anschlußkäufe kommen könnten (da Close am Tageshoch); beim Erreichen von 11 USD würde ich (zumindest) Teilgewinne realisieren 
Greetinxx Heinerle2
Greetinxx Heinerle2
Trading Spotlight
...immerhin bis 10.90 gekommen, bis sie wieder abgedreht hat. Wer nicht auf die letzten 10 Cent schaut, hat Teile einfließen lassen.
Greetinxx Heinerle2
Greetinxx Heinerle2
Falls noch jemand Stücke haben sollte - Close heute 13.59 USD
Greetinxx Heinerle2
- Close heute 13.59 USDGreetinxx Heinerle2
Close heute 15.86 USD , hoch bei 16.85 USD und somit quasi Komplett-Gap-Close. Seit meiner Vorstellung quasi gut verdoppelt. Wer noch Stücke haben sollte - ans rechtzeitige aussteigen denken, ich hab es mittlerweile *komplett* getan
Greetinxx Heinerle2
, hoch bei 16.85 USD und somit quasi Komplett-Gap-Close. Seit meiner Vorstellung quasi gut verdoppelt. Wer noch Stücke haben sollte - ans rechtzeitige aussteigen denken, ich hab es mittlerweile *komplett* getan Greetinxx Heinerle2
zur Info: Bei Regeneron wird spekuliert, dass sie mit "VEGF-Trap" ein wirksameres Mittel in der Pipeline haben als Genentech mit "Avastin". Wissenschafter schätzen die Wirksamkeit von "VEGF-Trap" höher ein. Das Produkt befindet sich jedoch noch in frühen Testphasen.
Viele grüße
Jörg
Viele grüße
Jörg
Regeneron buoyed by Aventis deal
Biotech firm in collaboration to develop cancer therapy
By Ted Griffith, CBS.MarketWatch.com
Last Update: 4:29 PM ET Sept. 8, 2003
BOSTON (CBS.MW) -- Shares of Regeneron Pharmaceuticals soared Monday after the small biotech firm announced a drug-development partnership with a potential value exceeding $500 million.
Free! Sign up here to receive Thom Calandra`s StockWatch e-Newsletter!
INFORMATION FOR AVE:
Create an alert for AVE
Add AVE to my portfolio
More cool charts on AVE
Discuss AVE
NEWS FOR AVE
Regeneron shares propelled by Aventis development deal
Biotech stocks close sharply higher, led by Regeneron
Banks, chips propel Europe to gains
More news for AVE
Quote & News Charts Financials Analysts Options SEC Filings
TRACK THESE TOPICS
My Portfolio Alerts
Company: Aventis Add
Create
Column: Screamers
Create
Company: Regeneron Pharmaceuticals Inc Add
Create
Company: Genentech Inc Add
Create
Get Breaking News sent directly to your inbox
Create A Portfolio | Create An Alert
Strasbourg, France-based Aventis (AVE: news, chart, profile) is making the deal with Tarrytown, N.Y-based Regeneron (REGN: news, chart, profile) to get the rights to the biotech firm`s promising experimental cancer therapy, still in the early phase of development.
Shares of Regeneron jumped $5.43, or 32.1 percent, to $22.31. U.S.-listed shares of Aventis added 29 cents to $51.53.
Under terms of the agreement, Aventis will initially pay $125 million -- $45 million to buy newly issued Regeneron stock and the remaining $80 million in an upfront payment. An additional $25 million payment is linked to achievement of an early clinical success.
After that, Aventis will pay Regeneron up to $360 million in success fees related to winning marketing approvals in the United States and Europe. Aventis has agreed to pay development costs, although if the collaboration is profitable, Regeneron would pay back to Aventis 50 percent of the drug`s development costs.
Regeneron has no products on the market and it has yet to show a profit.
If the experimental compound, known as a "VEGF Trap," reaches the market, the two companies will share equally in promotion rights and profits worldwide.
"We`re still getting 50 percent of the profits, so it`s a wonderful opportunity for us," Regeneron CEO Leonard Schleifer said in an interview with CBS MarketWatch. "We`re hoping this will be a significant win for people with cancer and that it will translate into a very big win for Regeneron and Aventis."
Schleifer declined, however, to estimate how long it will take to develop the compound.
Regeneron`s experimental therapy is designed to interfere with the blood vessel growth that fuels cancer`s deadly spread. The drug is now in early-stage, or Phase I, testing in patients with solid tumors and non-Hodgkin`s lymphoma.
The drug might also be used to treat eye diseases associated with abnormal blood vessel growth.
Scientists have long hoped that blocking abnormal blood vessel growth, a technique known as anti-angiogenesis, would prove to be an effective method of combating cancer.
Enthusiasm for anti-angiogenesis had been shaken by several clinical disappointments. But the field got a major boost earlier this year when No. 2 biotech firm Genentech (DNA: news, chart, profile) announced that its experimental anti-angiogenesis drug, Avastin, did better than expected at extending the lives of patients with advanced colon cancer.
The partnership with drugmaker Aventis was welcome news for Regeneron shareholders who endured a clinical setback early this year. Regeneron shares tumbled in late March after the biotech firm disclosed disappointing results for its experimental obesity therapy, called Axokine
Biotech firm in collaboration to develop cancer therapy
By Ted Griffith, CBS.MarketWatch.com
Last Update: 4:29 PM ET Sept. 8, 2003
BOSTON (CBS.MW) -- Shares of Regeneron Pharmaceuticals soared Monday after the small biotech firm announced a drug-development partnership with a potential value exceeding $500 million.
Free! Sign up here to receive Thom Calandra`s StockWatch e-Newsletter!
INFORMATION FOR AVE:
Create an alert for AVE
Add AVE to my portfolio
More cool charts on AVE
Discuss AVE
NEWS FOR AVE
Regeneron shares propelled by Aventis development deal
Biotech stocks close sharply higher, led by Regeneron
Banks, chips propel Europe to gains
More news for AVE
Quote & News Charts Financials Analysts Options SEC Filings
TRACK THESE TOPICS
My Portfolio Alerts
Company: Aventis Add
Create
Column: Screamers
Create
Company: Regeneron Pharmaceuticals Inc Add
Create
Company: Genentech Inc Add
Create
Get Breaking News sent directly to your inbox
Create A Portfolio | Create An Alert
Strasbourg, France-based Aventis (AVE: news, chart, profile) is making the deal with Tarrytown, N.Y-based Regeneron (REGN: news, chart, profile) to get the rights to the biotech firm`s promising experimental cancer therapy, still in the early phase of development.
Shares of Regeneron jumped $5.43, or 32.1 percent, to $22.31. U.S.-listed shares of Aventis added 29 cents to $51.53.
Under terms of the agreement, Aventis will initially pay $125 million -- $45 million to buy newly issued Regeneron stock and the remaining $80 million in an upfront payment. An additional $25 million payment is linked to achievement of an early clinical success.
After that, Aventis will pay Regeneron up to $360 million in success fees related to winning marketing approvals in the United States and Europe. Aventis has agreed to pay development costs, although if the collaboration is profitable, Regeneron would pay back to Aventis 50 percent of the drug`s development costs.
Regeneron has no products on the market and it has yet to show a profit.
If the experimental compound, known as a "VEGF Trap," reaches the market, the two companies will share equally in promotion rights and profits worldwide.
"We`re still getting 50 percent of the profits, so it`s a wonderful opportunity for us," Regeneron CEO Leonard Schleifer said in an interview with CBS MarketWatch. "We`re hoping this will be a significant win for people with cancer and that it will translate into a very big win for Regeneron and Aventis."
Schleifer declined, however, to estimate how long it will take to develop the compound.
Regeneron`s experimental therapy is designed to interfere with the blood vessel growth that fuels cancer`s deadly spread. The drug is now in early-stage, or Phase I, testing in patients with solid tumors and non-Hodgkin`s lymphoma.
The drug might also be used to treat eye diseases associated with abnormal blood vessel growth.
Scientists have long hoped that blocking abnormal blood vessel growth, a technique known as anti-angiogenesis, would prove to be an effective method of combating cancer.
Enthusiasm for anti-angiogenesis had been shaken by several clinical disappointments. But the field got a major boost earlier this year when No. 2 biotech firm Genentech (DNA: news, chart, profile) announced that its experimental anti-angiogenesis drug, Avastin, did better than expected at extending the lives of patients with advanced colon cancer.
The partnership with drugmaker Aventis was welcome news for Regeneron shareholders who endured a clinical setback early this year. Regeneron shares tumbled in late March after the biotech firm disclosed disappointing results for its experimental obesity therapy, called Axokine
Ist da eigentlich keiner mehr drin?
sobald meine nächste ration baldrian-tropfen eintreffen.
ohne substitute gehts bei der aktie nicht.
ich bin leider herzinfarkt verdächtig.
ohne substitute gehts bei der aktie nicht.
ich bin leider herzinfarkt verdächtig.
lalala 
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +0,02 | |
| -1,01 | |
| -0,42 | |
| -1,12 | |
| +0,95 | |
| -0,78 | |
| -0,58 | |
| -1,19 | |
| -0,72 | |
| -0,80 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 189 | ||
| 114 | ||
| 74 | ||
| 72 | ||
| 66 | ||
| 56 | ||
| 56 | ||
| 55 | ||
| 45 | ||
| 43 |
| Zeit | Titel |
|---|---|
| 28.12.23 |